ADC Therapeutics has announced a new restructuring plan that includes workforce reductions and cost-saving measures as the company concentrates resources on programs supporting its cancer therapy Zynlonta, following recent safety concerns that emerged from the LOTIS-5 confirmatory trial.
The Swiss antibody-drug conjugate developer said the reorganization is intended to focus resources on initiatives considered important for the continued development and commercialization of Zynlonta. According to the company, the changes will result in the elimination of approximately 17% of its global workforce and are expected to generate about $10 million in annual savings.
As of the end of 2025, ADC Therapeutics employed 188 full-time staff members. The company has already undergone significant workforce changes in recent years. A little more than a year ago, it announced a separate restructuring effort that reduced its global workforce by more than 30% and included the closure of a research facility in the United Kingdom. That earlier move followed the discontinuation of certain preclinical solid tumor programs and was also aimed at directing resources toward Zynlonta and other assets.
Under the latest restructuring plan, ADC Therapeutics expects to record a one-time charge of approximately $3 million related to severance payments, employee benefits and other termination-related expenses. The company anticipates recognizing most of these costs during the second quarter of 2026. ADC Therapeutics also stated that the reorganization is expected to extend its cash runway through at least 2028.
The company said the staff reductions are linked to the anticipated completion of the LOTIS-5 and LOTIS-7 studies this year, as well as operational efficiency measures. LOTIS-5 is the confirmatory trial designed to support full approval of Zynlonta in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). LOTIS-7 is a phase 1b study evaluating Zynlonta in combination with Roche’s bispecific therapy Columvi (glofitamab) in DLBCL.
ADC Therapeutics did not disclose which positions would be affected. However, the company said it would retain the resources necessary to carry out key clinical, regulatory and manufacturing activities while maintaining its medical affairs and commercial operations supporting Zynlonta.
The restructuring comes ahead of a planned meeting with the U.S. Food and Drug Administration in August. ADC Therapeutics intends to discuss a potential regulatory pathway for Zynlonta based on results from the LOTIS-5 trial, which it hopes will support conversion of the therapy’s accelerated approval into a full approval. The company said it plans to submit its application during the fourth quarter.
Earlier this month, ADC Therapeutics reported that 27 deaths occurred among patients receiving Zynlonta in the LOTIS-5 study, compared with nine deaths in the control group. Patients in the treatment arm received Zynlonta together with rituximab, while the control group received rituximab plus the chemotherapy agents gemcitabine and oxaliplatin.
Company executives said that most deaths in the Zynlonta arm occurred among patients aged 75 years and older and were associated with infections. They also suggested that differences in patient monitoring between study groups may have contributed to the higher number of reported deaths in the treatment arm.
The safety concerns largely overshadowed the positive topline results from the trial, which achieved its primary endpoint of progression-free survival. ADC Therapeutics’ share price fell approximately 52% following the announcement.
“As we further assess the Phase 3 LOTIS-5 trial outcomes, including feedback from key medical experts, we continue to believe in the favorable overall benefit-risk profile and look forward to our pre-supplemental Biologics License Application (sBLA) meeting with the U.S. Food and Drug Administration in August,” ADC Therapeutics Chief Executive Officer Ameet Mallik said in a statement.
Mallik also said that the reorganization is intended to provide greater financial flexibility as the company prepares for upcoming regulatory milestones related to LOTIS-5 while continuing work related to LOTIS-7 and support for investigator-initiated trials in indolent lymphoma.
ADC Therapeutics has announced a workforce reduction as part of a strategic effort to streamline operations and focus resources on advancing regulatory plans for Zynlonta. The restructuring reflects ADC Therapeutics’ commitment to improving operational efficiency while supporting the continued development and commercialization of its oncology portfolio.
ADC Therapeutics Refocuses Business Priorities
The latest restructuring allows ADC Therapeutics to align its workforce with its most important strategic objectives. By concentrating resources on Zynlonta and other high-priority programs, the company aims to strengthen its financial position and improve long-term growth opportunities.
Zynlonta Remains a Key Priority
For ADC Therapeutics, Zynlonta continues to be a central part of its oncology strategy. The company is advancing regulatory activities designed to expand the medicine’s potential use and strengthen its position within the treatment landscape for certain blood cancers.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
